Navigation Links
NeurogesX to Present at J.P. Morgan Health Care Conference
Date:1/16/2010

SAN MATEO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2009 at the Westin St. Francis Hotel in San Francisco, California.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during a 25-minute breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.


    Event:  28th Annual J.P. Morgan Healthcare Conference
    Date:   Thursday, January 14, 2009
    Time:   12:30 p.m. PT
    Place:  Westin St. Francis Hotel, San Francisco, CA (Elizabethan A/B)

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza® (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza®; the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Sara Pellegrino (investors)
    (646) 536-7002
    spellegrino@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com
    -----------------------

SOURCE NeurogesX, Inc.

RELATED LINKS
http://www.neurogesx.com

'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Piper Jaffray Health Care Conference
2. NeurogesX Reports Third Quarter 2009 Results
3. NeurogesX to Present at Two November Conferences
4. NeurogesX to Present at UBS Global Life Sciences Conference
5. NeurogesX to Present at Upcoming Fall Conferences
6. NeurogesX Appoints New Board Director and Audit Committee Chairman
7. NeurogesX Reports Second Quarter 2009 Results
8. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
9. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
10. NeurogesX Added to Russell 3000 Index
11. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or ... way to treat the disease. Surviving Mesothelioma has just posted an article on the ... Korean institutions based their mesothelioma study on the fact the Manumycin A, a derivative ...
(Date:5/19/2016)... (PRWEB) , ... May 19, 2016 , ... ... research organization (CRO) has welcomed Abu Siddiqui as Director, Large Molecule & Biomarker ... executing biologics, vaccine and translational biomarker discovery studies for preclinical and clinical safety ...
(Date:5/18/2016)... , May 18, 2016 The Biotech ... does not mean that there are no opportunities ahead. Today, ... Inc. (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... ), and Ophthotech Corp. (NASDAQ: OPHT ). Sign ... at: http://www.activewallst.com/ Threshold Pharmaceuticals ...
(Date:5/17/2016)... , May 18, 2016 Haselmeier ... prefilled pen following approval by EMA, the European Medicines ... science and technology company, the new pen version includes ... increased level of confidence to patients during use. ... prefilled pen easier to handle with a larger display ...
Breaking Biology Technology:
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
Breaking Biology News(10 mins):